Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
Legend Biotech presented first-in-human Phase 1 data for LB2102, a DLL3-targeted CAR-T therapy for solid tumors, at ASCO 2026. At higher dose levels, LB2102 achieved an objective response rate of 28.6% and a disease control rate of 78.6% in heavily pretreated patients with small cell lung cancer or large-cell neuroendocrine carcinoma.
Key figures
- Drug Name
- LB2102
- Phase Of Trial
- Phase 1
- Lb2102 dcr overall
- 70%
- Lb2102 orr overall
- 20%
- Carvykti os rate 30m
- >85%
- Lb2102 dcr high dose
- 78.6%
- Lb2102 orr high dose
- 28.6%
- Carvykti iec ec incidence
- 1.2%
- Carvykti patients treated
- 10,000+
- Lb2102 median duration control
- 6.1 months
- Lb2102 median duration response
- 6.5 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.